1. Myeloma Program, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL;
2. Clinica di Ematologia, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy;
3. Centre Hospitalier Universitaire de Grenoble–Hôpital Albert Michallon, Grenoble, France;
4. Hospital Universitario Doctor Peset and Universidad Católica “San Vicente Mártir,” Valencia, Spain;
5. Service d'hématologie, Hôpital Saint Antoine, Paris, France;
6. Department of Hematology, Centre Hospitalier, Le Mans, France;
7. Department of Hematology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy;
8. Department of Hematology, Azienda Ospedaliera Universitaria–Policlinico di Modena, Modena, Italy;
9. Department of Hematology/Oncology, Dana-Farber Cancer Institute, Boston, MA;
10. Division of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA;
11. Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico San Martino–Istituto Scientifico Tumori, Genoa, Italy;
12. Statistics, AbbVie Biotherapeutics Inc, Redwood City, CA;
13. Oncology Clinical Development, Bristol-Myers Squibb, Wallingford, CT;
14. Global Biometric Sciences, Bristol-Myers Squibb, Hopewell, NJ;
15. Exploratory Clinical and Translational Research–Oncology, Bristol-Myers Squibb, Princeton, NJ; and
16. Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy